595results about How to "Reduce rejection" patented technology

The present invention relates to collagenous membranes produced from amnion, herein referred to as a collagen biofabric. The collagen biofabric of the invention has the structural integrity of the native non-treated amniotic membrane, i.e., the native tertiary and quaternary structure. The present invention provides a method for preparing a collagen biofabric from a placental membrane, preferably a human placental membrane having a chorionic and amniotic membrane, by decellularizing the amniotic membrane. In a preferred embodiment, the amniotic membrane is completely decellularized. The collagen biofabric of the invention has numerous utilities in the medical and surgical field including for example, blood vessel repair, construction and replacement of a blood vessel, tendon and ligament replacement, wound-dressing, surgical grafts, ophthalmic uses, sutures, and others. The benefits of the biofabric are, in part, due to its physical properties such as biomechanical strength, flexibility, suturability, and low immunogenicity, particularly when derived from human placenta.

A woven mesh is provided for supporting tissue or an organ within a female patient's pelvis, and a method for using the same. The mesh includes a central portion having a width, a length, first and second ends, and first and second side edges, and first and second wing portions extending from the first and second ends of the central portion respectively. The first and second wing portions each have a width, a length, and first and second peripheral edges. The width of the wing portions are each greater than the width of the central portion, and when positioned within the female patient, the central portion is positioned below and supports the tissue or organ. A mesh is also provided having woven fibers with voids therebetween, and having a central portion and first and second ends. The average size of the voids at least in the central portion is at least 25–50 mm2, and when positioned within the patient, the central portion is positioned below and supports the tissue or organ.

A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.

As a substrate (10) is carried on a conveyor (20), an image analysis system (40) detects its presence and derives the various data, at least indicative of the footprint. The footprint data are used in selecting appropriate packaging components. Data may also indicate the transverse location and / or orientation and / or alignment of a substrate, and be used to control position adjustors for adjusting one or more of these. Data may also serve for categorizing the substrate, e.g., in terms of size or color. Such data may be used to control rejection of products, or categorization, e.g., by selection of distinguishable packaging.

Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCRα, TCRβ, or CD3ε, along with compositions and methods of use thereof are provided.

The invention provides methods to diagnose and follow the progression of disease through use of protein profile analysis.

The present invention concerns compounds comprising, within short sequences from a specific region of the kinase, that can modulate kinase-associated signal transduction.

The invention relates to a method for preparing a small intestinal submucosa (SIS) soft tissue repair patch, and the soft tissue repair patch prepared by the method. The invention also relates to application of the soft tissue repair path to tissue repair.

Verification of Caller identification, used independently of caller ID or as an adjunct to caller ID for caller verification by matching caller voice samples to voice samples previously stored. Verification algorithms can be implemented as a stand alone device connected to the telephone line or the interne, in software which can be a resident on a PSTN phone, mobile phone or an IP phone or resident on a computer. Voice samples of the current caller are recorded and compared a database of previously recorded voice samples. When a call is received for the first time, the caller records the caller's name which is stored into a database and correlated with the received caller ID information of the present caller, if such information was received. If no caller ID information is received, the voice sample is stored in the database with an indication of a lack of caller ID information. The collection and storage of voice samples allows the use of such samples for voice authentication if the caller calls again. When a caller calls again, the caller records the caller's name as the current caller's voice sample which is compared to the stored database. The enhanced accuracy will aid in acceptance and rejection decisions as well as decisions regarding the handling of incoming telephone calls and will aid in the retrieval of additional information regarding the caller if available.

A method of operating a printing machine and a printing machine apparatus in which basic knowledge about the interaction between operating media in the printing machine is obtained through printing trials or during production. This knowledge is stored in an expert system and made available for the printing operation or else for the production of the printing plate. The expert system is preferably a self-teaching system. For color reproduction, basic calibrations are carried out in a first quality step, in a second step, the imaging operation is adapted to the areas and half tones to be imaged, and ink-density regulation is carried out in a third step.

The invention belongs to the field of immunotherapy and relates to a universal CAR-T cell and a preparation method and application thereof. In the universal CAR-T cell, the functions of a T cell antigen receptor (TCR) and major histocompatibility complexes (MHC I and MHC II) in the T cell are inhibited while multi-gene knockout is performed; a gene encoding the TCR includes TRAC and / or TRBC; genesencoding the major histocompatibility complexes include HLA-A, B2MH and CIITA. The universal CAR-T cell can target relevant markers of specific tumors and inactivate the functions of the TCR and theMHC on the cell surface, can reduce immunological rejection caused by allogeneic cell therapy and safely and effectively remove tumor cells in the diseased human body, is not affected by the disease or a treatment mode of a patient in use and can be prepared at any time, treatment can be provided at the optimum time, and treatment effectiveness is ensured.

A system for obtaining a signature from a scan area on the surface of an article comprises: a signature generator that generates the signature from scattered coherent radiation detected from a plurality of points on the surface and includes a scan head comprising a coherent radiation source and photodetectors; a camera for capturing an image of the surface; a comparator that compares the captured image with a reference image to determine the location and orientation of the scan area; and a drive assembly that positions the scan head appropriately for generating a signature from the scan area in response to the determination of the location and orientation of the scan area.

The invention provides artificial articular cartilage based on autologous cells and a preparation method thereof. The artificial articular cartilage comprises a nano bionic support and hydrosol adhered to the nano bionic support, wherein one or more cytokines are coated into the hydrosol. The invention also provides the method for preparing the artificial articular cartilage, which comprises the following steps: preparing an electrostatic spinning solution, a cytokine-containing hydrosol solution and a crosslinking agent solution; using the crosslinking agent solution to receive electrostatic spinning so as to prepare the nano bionic support; and using an ink jet printer to print the cytokine-containing hydrosol solution on the nano bionic support, and curing the hydrosol to obtain the artificial articular cartilage. The three-dimensional support adopted by the invention has ideal degradation speed and is degraded after the regeneration of an articular cartilage layer, can meet the requirement of actual clinical application, can be completely degraded, and has good abrasion resistance and lubricity so as to be capable of replacing the cartilage before the regeneration of the articular cartilage layer.

The present technology is related to the field of bone-tendon-bone implants, grafts, and components thereof, for implantation in mammals, particularly for implantation in humans. More particularly, the present technology relates to assembled implants that comprise a length of tendon and at least two bone components or intermediate bone blocks that are assembled to form a bone-tendon-bone implant, and methods of making such implants. In some embodiments, implants of the present technology provide a first grip on the tendon prior to implantation and a second grip during or after implantation. In some embodiments, bone block assemblies or intermediate bone blocks of the present technology have a first geometric configuration prior to implantation and a second geometric configuration during or after implantation.

Medical device and methods are provided for controlled drug delivery in a cardiac patient. The device includes an implantable drug delivery module comprising reservoirs containing a drug and a control means for selectively releasing an effective amount of drug from each reservoir; one or more electrodes or sensors for cardiac monitoring, stimulation, or both; and a microcontroller for controlling operational interaction of the drug delivery module and the cardiac electrode. The electrodes may comprise ECG monitoring, cardioversion, or cardiac pacing electrodes. A medical device also is provided for controlled delivery of drug to a patient having congestive heart failure, which includes an implantable drug delivery module comprising a natriuretic peptide and a release mechanism for selectively releasing a pharmaceutically effective amount of the natriuretic peptide into the patient; and a microcontroller for controlling the release mechanism, for example, in response to one or more monitored patient parameters.

The invention discloses biological ink material for 3D printing and a preparation method and application thereof. The biological ink material is prepared by, by mass concentration percentage, 5-18% of biological macromolecules, 76-93.5% of water or 76-93.5% of pre-crosslinking agent, and 1.5-6% of coagulant, wherein the sum of the mass concentration percentage of the above raw materials is 100%. The biological ink material is characterized in that water washing and crosslinking are performing for shaping after printing. The biological ink material has the advantages that the biological ink material can be easily squeezed out during printing, does not block printing needles and can be easily shaped after being squeezed out; the biological ink material is low in antigenicity in the bodies of organisms, low in caused rejection reaction, biodegradable, nontoxic to the organisms and high in safety.

An example system for inducting air into an engine includes a compressor and a turbine mechanically coupled to the compressor and driven by expanding engine exhaust. The system also includes a first conduit network configured to route some engine exhaust from a take-off point downstream of the turbine to a mixing point upstream of the compressor, and, a second conduit network configured to route some engine exhaust from a take-off point upstream of the turbine to a mixing point downstream of the compressor. The first and second conduit networks in the system have a shared conduit and a control valve configured to adjust an amount of engine exhaust flowing through the first conduit network and to adjust an amount of engine exhaust flowing through the second conduit network. The system also includes a flow sensor coupled in the shared conduit.

The present invention provides a liquid repellent membrane whose liquid repellency can be controlled by a varying physical stimulation; a novel fluorine compound which can be formed into the liquid repellent membrane; an electrical board, display device and color filter for display devices which are formed using the liquid repellent membrane by a method involving irradiation of visible light, which may be combined with a heating step, but needing no vacuum or ultraviolet ray irradiation process; methods for producing an electrical board, display device and color filter for display devices; and a pH sensor and ion sensor working on measurement of changed liquid repellency. The fluorine compound having liquid repellency is provided with a site at which it can be bound to a functional group, e.g., compound having a pigment unit.

The invention relates to altered immune cells and their use in methods and compositions to alter the immune system in a mammal. More specifically, the invention is directed to the alteration of gene expression in antigen presenting cells such as dendritic cells (DC) and their use in various methods and compositions to alter T cell activity for the treatment of a variety of immune disorders.

Compounds and methods for sorbing organosulfur compounds from fluids are provided. Generally, compounds according to the present invention comprise mesoporous, nanocrystalline metal oxides. Preferred metal oxide compounds either exhibit soft Lewis acid properties or are impregnated with a material exhibiting soft Lewis acid properties. Methods according to the invention comprise contacting a fluid containing organosulfur contaminants with a mesoporous, nanocrystalline metal oxide. In a preferred embodiment, nanocrystalline metal oxide particles are formed into pellets (14) and placed inside a fuel filter housing (12) for removing organosulfur contaminants from a hydrocarbon fuel stream.

An EGR mixer comprises an upstream conduit section having a contracting flow area in a direction of air flow through the mixer, a downstream conduit section having an expanding flow area in the direction of air flow through the mixer, a slot formed in the downstream conduit section for admitting exhaust to the air flow, and an abrupt flow-expanding ridge disposed between the upstream and downstream conduit sections. With the EGR mixer configured in this manner, recirculated exhaust may be effectively homogenized into an intake air flow with reduced drag.

A composite semipermeable membrane which combines the high ability to reject salts and a high permeation flux and is especially excellent in the ability to reject uncharged substances, and a process for producing the semipermeable membrane are disclosed. The process comprises forming on a surface of a porous supporting film a thin film comprising a polyamide resin obtained by reacting a polyfunctional amine ingredient with a polyfunctional acid ingredient in the presence of at least an alkali metal hydroxide and an organic acid.

The invention relates to a method for applying rewiring to a panel. For this purpose, a panel is provided which has a coplanar overall upper side of an upper side of a plastic compound and the upper sides of semiconductor chips. The method provides a rewiring layer with implementation of external contacts and rewiring lines which, by means of a two-stage exposure step, compensates for position errors of the semiconductor chips in the component positions of the panel.

Disclosed is a method of inducing a reduced immune response to a transplant in a recipient by treating said recipient with an amount of fibroblasts or a supernatant from a fibroblast culture effective to reduce or inhibit host rejection of the transplant. The fibroblasts or a supernatant from a fibroblast culture can be administered before, at the same time as, or after the transplant. This method is effective in reducing an immune response to a transplant without compromising the immune response to other foreign antigens. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease.

A biological sample collection and test kit and a method of using the kit are disclosed in the application. The kit includes a swab, having a sample collection portion, a cover for covering the sample collection portion of the swab for hygienic purpose. Also disclosed is a package for the swab and the cover.